Related Experiment Videos
[New analogues of methotrexate]
1Fourth Dept. of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 1, 1992
Summary
New antifolate antimetabolites, including Trimetrexate, Edatrexate, and TNP-351, are in clinical trials for lung cancer. These methotrexate analogues show varied cellular uptake and efficacy, offering new chemotherapy options.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Context:
- Development of novel antifolate antimetabolites is ongoing.
- Three methotrexate analogues (Trimetrexate, Edatrexate, TNP-351) are in clinical trials in Japan.
Purpose:
- To review the current status of clinical trials for three new antifolates.
- To discuss their potential indications in lung cancer chemotherapy.
Summary:
- Trimetrexate utilizes passive transport for cell entry, differing from methotrexate.
- Edatrexate is anticipated to have higher therapeutic efficacy due to increased polyglutamate concentrations in tumor cells.
- TNP-351 is a novel antifolate with a distinct chemical structure.
Impact:
- These agents represent potential advancements in lung cancer treatment.
- Understanding their mechanisms may guide future drug development.
- Clinical trial data will inform their therapeutic application.